Directory
Research PeptidesGROWTH HORMONE AXIS
Evidence grade C
CJC-1295 w/DAC
Small human pharmacology studies in healthy volunteers; no completed efficacy trial in any patient group, and development stopped in phase 2.
- Strengths
- 5, 10 mg
- Also known as
- CJC-1295, DAC:GRF, CJC-1295 with Drug Affinity Complex
- Molecule
- 29-amino-acid GHRH analog plus a lysine carrying an albumin-binding (DAC) group
- Formula
- C165H269N47O46
- Mol. weight
- 3647.25 g/mol
- CAS
- 446262-90-4 (reference value)
Origin
Developed by ConjuChem in the early 2000s. It is the same modified GRF (1–29) backbone as CJC-1295 No DAC, with an extra lysine carrying a maleimide "drug affinity complex" that bonds to albumin in the blood.
How it works
Activates pituitary GHRH receptors so the pituitary releases growth hormone, raising IGF-1. Because it rides on albumin, stimulation lasts for days. In healthy men, growth hormone pulses kept their normal timing while baseline levels rose sharply.
What the research shows
Two small 2006 studies in healthy adults reported that a single dose raised growth hormone 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days, with a half-life of about 6–8 days. A phase 2 trial in HIV-associated abdominal fat was halted in 2006 after a participant died; no efficacy results were published and the program never resumed. Clinical benefit in any condition and long-term safety of continuously raised growth hormone are unknown.
Key studies
- Teichman et al., JCEM 2006 Healthy adults: GH up 2–10-fold for 6+ days and IGF-1 up 1.5–3-fold for 9–11 days after one dose.
- Ionescu & Frohman, JCEM 2006 Healthy men: trough GH up 7.5-fold and IGF-1 up 45%, with pulse pattern preserved.
- Jetté et al., Endocrinology 2005 Rats: bound to albumin beyond 72 hours; about 4 times more GH release than unmodified GRF.
Safety findings
The 2006 studies reported no serious adverse reactions. FDA's review cites increased heart rate, a systemic flushing-type reaction and immunogenicity as concerns. A participant death in the 2006 HIV trial was reportedly judged unrelated by the treating physician, but the program stopped. Its week-long action means effects cannot be quickly reversed.
Regulatory status
Not FDA-approved; development ended in 2006. FDA's compounding advisory committee voted 0–13 against each DAC form in December 2024, so no lawful 503A pathway was confirmed. Prohibited at all times by WADA (S2.2.4 names CJC-1295).
Catalog notes
Available in 5 and 10 mg. No purity figure or certificate is published yet; the catalog directs certificate requests to support. No CAS or sequence is listed.